Lutetium-177 PSMA Prostate Radioligand Therapy Program

• Terapia com Lutécio-177
• Consulta com um médico
• Exames de sangue
• Exame de acompanhamento

• Transfer aeroporto-clínica-aeroporto

Lutetium-177 PSMA Prostate Radioligand Therapy Program

The Lutetium-177 (Lu-177) PSMA Prostate Radioligand Therapy Program is an advanced targeted treatment option for patients with metastatic, progressive, or treatment-resistant prostate cancer. This program provides a structured and carefully monitored therapeutic pathway designed for precise tumor targeting and controlled systemic treatment.

Prior to therapy, previously performed PSMA PET/CT imaging is reviewed to confirm adequate PSMA receptor expression and to evaluate disease distribution. Based on this molecular imaging assessment, treatment eligibility and final therapy planning are determined individually.

The therapy utilizes Lutetium-177, a beta-emitting radioisotope linked to a PSMA-targeting molecule that selectively binds to prostate cancer cells. After binding and internalization, Lutetium-177 delivers targeted radiation to tumor tissue, leading to DNA damage and controlled destruction of cancer cells while minimizing exposure to surrounding healthy tissues.

The radiopharmaceutical is produced in Non-Carrier-Added (NCA) quality, providing high specific activity and optimized therapeutic performance.

Due to the moderate tissue penetration range of beta radiation, Lu-177 PSMA therapy enables effective treatment of metastatic lesions while maintaining a favorable safety profile. This therapy is widely used for advanced prostate cancer patients requiring systemic targeted treatment.

The program is conducted under the medical supervision of Assoc. Prof. Dr. Kezban Berberoğlu, Director of Nuclear Medicine, with more than 20 years of experience in nuclear medicine and advanced molecular imaging. All treatments are administered in a specialized nuclear medicine environment under strict safety and monitoring protocols.

The therapeutic compound is sourced through internationally regulated pharmaceutical supply channels, including certified medication suppliers in the United States, ensuring high manufacturing standards, quality control, and traceability.

Nuclear medicine consultation
Comprehensive laboratory testing to assess kidney, liver, and hematologic function
MAG-3 renal scintigraphy
Administration of Lutetium-177 PSMA therapy
Post-treatment imaging
Coordinated follow-up by a nuclear medicine specialist, including verification of residual radioactivity to ensure flight compatibility

The recommended stay is approximately three days per treatment cycle, including arrival and departure, provided no significant side effects or unexpected medical events occur. If necessary, monitoring may be extended to ensure patient safety.

For patient convenience, cost-efficient partner hotels are available near the hospital, offering daily shuttle service between the hotel and the medical center to ensure smooth and organized logistics throughout the treatment process.

• Coordenador médico pessoal
• Arranjos de viagem médica — reserva de passagens aéreas e quartos de hotel com preços especiais de parceiros
• Defesa do paciente durante a viagem médica